-+ 0.00%
-+ 0.00%
-+ 0.00%

Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071

Reuters·12/18/2025 13:00:30

Please log in to view news